Elevai Labs, a medical aesthetic company specializing in physician-dispensed skincare, announced the pricing of its initial public offering.

WHO: Elevai Labs is a medical aesthetic company developing cutting-edge physician-dispensed skincare applications, solving an unmet need in the medical aesthetics space. Elevai Labs develops topical aesthetic skincare products for the physician-dispensed market, with a focus on leveraging a proprietary stem cell exosome technology.

WHY: The proceeds of the Nasdaq listing will be used to expand the sales force, new product innovation, general working capital, and marketing.

IN THEIR OWN WORDS: Elevai Labs CEO and co-founder Jordan Plews shared, “We are thrilled about our debut on the Nasdaq Capital Markets. This milestone and access to capital markets are poised to fuel the growth of our brand in the physician-dispensed skincare sector. Notably, it’s common in our industry for companies to wait until later in their development to go public. But, in a trailblazing move, we’ve chosen an early public listing. We’re confident this strategy will not only set a precedent for others but also potentially reshape the way financings are done within our market.” 

DETAILS:

• Elevai Labs lists on the Nasdaq Capital Market and will trade under the ticker symbol ELAB.
• The offering consists of 1,500,000 shares of common stock at a public offering price of $4.00 per share, for total gross proceeds of $6,000,000 before deducting underwriting discounts and offering expenses. 
• Univest Securities and Webull Financial are acting as co-underwriters for the offering. Ortoli Rosenstadt LLP is acting as US counsel to the company, and Hunter Taubman Fischer & Li LLC is acting as US counsel to the underwriters in connection with the offering.